#Cancer Research #Netherlands #Rotterdam #SkylineDx #CSCC

SkylineDx Presents New Findings on Cutaneous Squamous Cell Carcinoma

SkylineDx, a pioneer in molecular diagnostics for dermatology based in Rotterdam, Netherlands, is set to make significant contributions to the field of skin cancer research at the upcoming 83rd Society for Investigative Dermatology Annual Meeting held in Chicago from May 13-16. The company will present groundbreaking data through two oral presentations and an e-poster that will deepen the understanding of cutaneous squamous cell carcinoma (CSCC).

Importance of Their Research

CSCC is already known as the second most prevalent form of skin cancer across the globe. While most cases are benign and manageable, around 2-5% of patients face severe challenges due to the potential for metastasis, ultimately leading to dire health ramifications. With CSCC often left unaddressed in major cancer registries, SkylineDx’s mission aims to bridge that knowledge gap through genomic and transcriptomic analysis of the disease.

The forthcoming presentations will introduce a novel gene expression signature designed specifically for CSCC, promising enhanced capability in identifying patients at high risk of metastatic progression—an advance over traditional staging systems. To put it in perspective, gone are the days when treatment solely relied on broad categorization; now, the spotlight is shifting towards genomic details that can more accurately predict individual outcomes.

Key Presentations

Comprehensive Genomic Characterization of CSCC

In an effort to decode the genomic intricacies of CSCC, SkylineDx integrated extensive data from four national databases in the Netherlands to develop a cohort that links clinically annotated tumors to patient outcomes. An analysis involving RNA-sequencing on 366 tumors and whole-exome sequencing on 147 tumors reveals a more tangible molecular picture of CSCC. The outcomes promise improved insights regarding biomarkers associated with unfavorable prognoses.

Genetic Alterations of HLA Class I Genes

The team’s findings explored the high mutation burden characteristic of CSCCs and their immunogenic nature, while filling the gaps associated with antigen presentation mutations. The researchers scrutinized the germline diversity of human leukocyte antigen (HLA) genes to examine their role in cancer vulnerability. Ultimately, the results suggest that inherited genetic traits combined with somatic mutations might notably reduce the capacity for antigen presentation, facilitating keratinocyte carcinogenesis.

E-Poster Presentation: Predicting Metastatic Risk with Gene Expression

SkylineDx’s e-poster will present a cutting-edge gene expression profile dubbed SCCore GEP, particularly effective in refining metastatic risk stratification protocols. This study acknowledges that over one-third of metastatic cases arise in patients initially classified as low risk (T1, T2a), the vast majority of cases accounting for 90% of the patient population. This innovative signature seeks to illuminate additional biological risk factors often missed by traditional clinical metrics.

Implications of the Findings

Dr. Hunter Shain from the University of California, San Francisco, emphasized the study's remarkable capacity for identifying promising biomarkers that may complement or surpass established cancer staging systems. SkylineDx’s CEO, Dharminder Chahal, underlined the importance of these insights in improving patient outcomes and risk stratification; a mission that aligns with the company's history and commitment to advancing cancer diagnostics.

Conclusion

SkylineDx’s work at the Society for Investigative Dermatology Annual Meeting is set to resonate widely across the research community. With their meticulous approach and innovative solutions, they prepare to uncover new strategies in clinical settings that could ultimately enhance the survival rates and quality of life for CSCC patients. To keep up with their advancements, visit their official website at SkylineDx.